TheraRadar
Data updated: May 26, 2026

Obizur (antihemophilic factor (recombinant), porcine sequence)

Approved 2014-10-22
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
11
Years on Market

Details

Status
Prescription
First Approved
2014-10-22
Patent Cliff
2021

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
Intravenous
Dosage Forms
For Injection

Companies

Takeda
Active Ingredient: Antihemophilic Factor (Recombinant), Porcine Sequence

Obizur Approval History

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2014 to 2014
Oct 2014 ORIGINAL
Update · CBER biologic (Purple Book)

What Obizur Treats

1 FDA approvals

Originally approved for its first indication in 2014 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

Obizur FDA Label Details

Track Obizur with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

FDA Approval: BLA125512 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.